Abstracts tagged "Abatacept"

Abstract Number: 948 • 2016 ACR/ARHP Annual Meeting
Subcutaneous Abatacept in Patients with Polyarticular-Course Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Efficacy and Safety
DJ Lovell¹, N Ruperto², N Tzaribachev³, G Vega-Cornejo⁴, I Louw⁵, A Berman^6,7, I Calvo⁸, R Cuttica⁹, G Horneff¹⁰, F Avila-Zapata¹¹, J Anton¹², R Cimaz¹³, E Solau-Gervais¹⁴, R Joos¹⁵, G Espada¹⁶, X Li¹⁷, M Nys¹⁸, R Wong¹⁷, S Banerjee¹⁷, Hermine I. Brunner¹⁹, A Martini²⁰ and For Pediatric Rheumatology International Trials Organization (PRINTO)/Pediatric Rheumatology Collaborative Study Group (PRCSG), ¹Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Istituto G. Gaslini Pediatria II Reumatologia, Genoa, Italy, ³Pediatric Rheumatology, Bad Bramstedt, Germany, ⁴Clinica de Rheumatología y Enfermedades Autoinmunes (CREA), Hospital México Americano, Guadalajara Jalisco, Mexico, ⁵Panorama Medical Centre, Cape Town, South Africa, ⁶Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucumán, Argentina, ⁷Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucuman, Argentina, ⁸Hospital Univ. La Fe, Valencia, Spain, ⁹Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, ¹⁰Centre Paediatric Rheumatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹¹Star Medica Hospital, Merida, Mexico, ¹²Unitat de Reumatologia Pediàtrica, Hospital Sant Joan de Déu, Barcelona, Spain, ¹³Pediatrics, Ospedale Pediatrico Anna Meyer, Florence, Italy, ¹⁴Hôpital de la Miletrie, Poitiers, France, ¹⁵University Hospital Gent, Gent, Belgium, ¹⁶Cramer 1853 4°C, Hospital de Ninos Dr Ricardo Gutierrez, Buenos Aires, Argentina, ¹⁷Bristol-Myers Squibb, Princeton, NJ, ¹⁸Bristol-Myers Squibb, Braine-l’Alleud, Belgium, ¹⁹Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²⁰Istituto G. Gaslini Pediatria II Reumatologia and University of Genova, Genoa, Italy
Background/Purpose: IV abatacept (ABA) 10 mg/kg every 4 weeks was well tolerated and effective in reducing the signs and symptoms of polyarticular-course juvenile idiopathic arthritis…
Abstract Number: 2613 • 2016 ACR/ARHP Annual Meeting
Seropositivity for RF or ACPA Predicts Long Term Drug Retention with Rituximab, but Not with Abatacept and Tocilizumab : Long-Term Registry Data in 4498 Patients with Rheumatoid Arthritis
Jacques-Eric Gottenberg¹, Jacques Morel², Arnaud Constantin³, Thomas Bardin⁴, Alain G. Cantagrel⁵, Bernard Combe⁶, Maxime Dougados⁷, Rene-Marc Flipo⁸, Alain Saraux⁹, Thierry Schaeverbeke¹⁰, Jean Sibilia¹¹, Martin Soubrier¹², Olivier Vittecoq¹³, Elodie Perrodeau¹⁴, Philippe Ravaud¹⁵, Xavier Mariette¹⁶ and on behalf of the French Society of Rheumatology and of all the investigators participating to the AIR, ORA and REGATE registries, ¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, ³Rheumatology, CHU Purpan - Hopital Pierre-Paul Riquet, Toulouse, France, ⁴Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, ⁵Rheumatology, Centre Hospitalier Universitaire, Toulouse Purpan, Toulouse, France, ⁶Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁷Rheumatology, Paris Descartes University, Paris, France, ⁸Rheumatology, University Hospital, Lille, France, ⁹Rheumatology, Brest University Hospital, Brest, France, ¹⁰Rheumatology, CHU Bordeaux, Bordeaux, France, ¹¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹²Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹³Rheumatology, Rouen University Hospital &INSERM U905, Rouen, France, ¹⁴Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ¹⁵Epidemiologist, PARIS, France, ¹⁶Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France
Background/Purpose: Seropositivity for RF or ACPA is associated with a better short-term effectiveness and drug retention of abatacept (ABA) and rituximab (RTX). Data are very…
Abstract Number: 979 • 2016 ACR/ARHP Annual Meeting
A Randomized Double-Blind Trial of Abatacept and Glucocorticoids for the Treatment of Takayasu’s Arteritis
Carol A. Langford¹, David Cuthbertson², Steven R. Ytterberg³, Nader A. Khalidi⁴, Paul A. Monach⁵, Simon Carette⁶, Philip Seo⁷, Larry W. Moreland⁸, Michael Weisman⁹, Curry L. Koening¹⁰, Antoine G. Sreih¹¹, Robert F. Spiera¹², Carol A McAlear¹³, Kenneth J. Warrington³, Christian Pagnoux¹⁴, Kathleen Maksimowicz-McKinnon¹⁵, Lindsy J. Forbess⁹, Gary S. Hoffman¹⁶, Renee Borchin¹⁷, Jeffrey Krischer¹⁷ and Peter A. Merkel¹⁸, ¹Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴McMaster University, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁵Rheumatology, Boston University School of Medicine, Boston, MA, ⁶Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁸Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Rheumatology, University of Utah, Salt Lake City, UT, ¹¹Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹²Hospital for Special Surgery, Cornell, New York, NY, ¹³Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹⁶Rheumatology, Cleveland Clinic, Cleveland, OH, ¹⁷University of South Florida, Tampa, FL, ¹⁸Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Takayasu’s arteritis (TAK) is a large-vessel primary systemic vasculitis that affects the aorta, its branches, and the pulmonary arteries. Despite treatment with glucocorticoids, relapse…
Abstract Number: 2614 • 2016 ACR/ARHP Annual Meeting
Similar Rates of Death, Serious Infections, Cancers, Major Cardiovascular Events in Patients Treated with Abatacept, Rituximab and Tocilizumab: Long-Term Registry Data in 4498 Patients with Rheumatoid Arthritis
Jacques-Eric Gottenberg¹, Jacques Morel^2,3, Arnaud Constantin⁴, Thomas Bardin⁵, Alain Cantagrel^6,7, Bernard Combe⁸, Maxime Dougados^9,10, Rene-Marc Flipo¹¹, Alain Saraux¹², Thierry Schaeverbeke¹³, Jean Sibilia¹⁴, Martin Soubrier¹⁵, Olivier Vittecoq¹⁶, Elodie Perrodeau¹⁷, Philippe Ravaud¹⁸, Xavier Mariette¹⁹ and on behalf of the French Society of Rheumatology and of all the investigators participating to the AIR, ORA and REGATE registries, ¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, ³Immuno-Rheumatology, University Hospital of Lapeyronie, University Montpellier 1, Montpellier, France, ⁴Rheumatology, CHU Purpan - Hopital Pierre-Paul Riquet, Toulouse, France, ⁵Service de Rhumatologie. Centre Viggo Petersen. Hôpital Lariboisière, Paris, France, ⁶Rheumatology, INSERM CNRS UMR 1043, Paul Sabatier University Toulouse, Purpan Teaching Hospital, Toulouse, France, ⁷Rheumatology, Purpan University Hospital, Toulouse Cedex 9, France, ⁸Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁹Rheumatology, Paris Descartes University, Paris, France, ¹⁰René Descartes University and Hôpital Cochin, Paris, France, ¹¹Rheumatology, Hopital R Salengro CHRU, Lille, France, ¹²Rheumatology, Brest University Hospital, Brest, France, ¹³Rheumatology, CHU Bordeaux, Bordeaux, France, ¹⁴Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹⁵Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹⁶Rheumatology, Rouen University Hospital &INSERM U905, Rouen, France, ¹⁷Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ¹⁸Epidemiology, Hotel Dieu, PARIS, France, ¹⁹Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France
Background/Purpose: Assessment of safety in randomized controlled trials is limited by trial durations, and selection of patients with few or now comorbidities. Such limitations can…
Abstract Number: 1041 • 2016 ACR/ARHP Annual Meeting
Abatacept in the Treatment of Active Psoriatic Arthritis: 24-Week Results from a Phase III Study
P Mease¹, AB Gottlieb², D van der Heijde³, Oliver FitzGerald⁴, A Johnsen⁵, M Nys⁶, S Banerjee⁵ and D Gladman⁷, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Tufts University School of Medicine (affiliation at the time of the study), Boston, MA, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Rheumatology, St Vincent’s University Hospital and University College Dublin, Dublin, Ireland, ⁵Bristol-Myers Squibb, Princeton, NJ, ⁶Bristol-Myers Squibb, Braine-l’Alleud, Belgium, ⁷Rheumatology, University of Toronto and Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Abatacept (ABA), a selective T-cell co-stimulation modulator, showed promise for the treatment of PsA in a Phase II trial.1 This prompted the conduct of…
Abstract Number: 2628 • 2016 ACR/ARHP Annual Meeting
Retention of Use and Safety of Subcutaneous Abatacept in Rheumatoid Arthritis: A Patient Record Assessment in a Compassionate Use Programme in South Africa, a Tuberculosis Endemic Country
I Louw¹, M Ally², DC Janse van Rensburg², E Van Duuren³, D Nel³, H Miller-Janson⁴, M de Necker⁴, JC de Beer⁴ and H Duvenhage⁵, ¹Panorama Medical Centre, Cape Town, South Africa, ²University of Pretoria, Pretoria, South Africa, ³Jacaranda Hospital, Pretoria, South Africa, ⁴HEXOR (PTY) Ltd, Pretoria, South Africa, ⁵Bristol-Myers Squibb, Johannesburg, South Africa
Background/Purpose: South Africa is a tuberculosis (TB) endemic country having one of the highest TB infection rates in the world with close to 1000 cases…
Abstract Number: 1565 • 2016 ACR/ARHP Annual Meeting
Gene Modules Correlated with Disease Activity and Abatacept Treatment Identified with Weighted Gene Co-Expression Network Analysis of CD4+ T Cell Subsets of RA
Shuji Sumitomo¹, Yasuo Nagafuchi¹, Yumi Tsuchida¹, Haruka Tsuchiya¹, Mineto Ota¹, Kazuyoshi ishigaki², Shinichiro Nakachi¹, Rika Kato¹, Keiichi Sakurai¹, Norio Hanata¹, Shoko Tateishi³, Hiroko Kanda³, Akari Suzuki⁴, Yuta Kochi⁴, Keishi Fujio¹ and Kazuhiko Yamamoto¹, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Laboratory for Statistical Analysis, Center for Integrative Medical Sciences, The Institute of Physical and Chemical Research (RIKEN), Yokohama, Japan, ³Department of Immunotherapy Management, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ⁴Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan
Background/Purpose: Although there are several reports of transcriptome analysis of peripheral blood mononuclear cells (PBMC) in RA, analysis of detailed CD4+ subset and the effect…
Abstract Number: 1583 • 2016 ACR/ARHP Annual Meeting
Body Mass Index Does Not Affect Response to Subcutaneous or Intravenous Abatacept in Patients with Rheumatoid Arthritis
MA D'Agostino¹, R Alten², E Mysler³, M Le Bars⁴, J Ye⁵, B Murthy⁵, J Heitzmann⁶, R Vadanici⁴ and G Ferraccioli⁷, ¹Hôpital Ambroise Paré, Boulogne-Billancourt, France, ²Schlosspark-Klinik University Medicine, Berlin, Germany, ³Organización Médica de Investigación, Buenos Aires, Argentina, ⁴Bristol-Myers Squibb, Rueil-Malmaison, France, ⁵Bristol-Myers Squibb, Princeton, NJ, ⁶Excelya, Boulogne-Billancourt, France, ⁷Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: High BMI is associated with reduced remission rates with anti-TNF agents in RA.1,2 In ACQUIRE (NCT00559585), SC and IV abatacept (ABA) achieved similar ACR20…
Abstract Number: 1589 • 2016 ACR/ARHP Annual Meeting
Body Mass Index Does Not Impact Abatacept Retention in Biologic-Naive Patients with Rheumatoid Arthritis Who Have Poor Prognostic Factors: A 12-Month Interim Analysis of an Observational, Prospective Study
R Alten¹, H-M Lorenz², HG Nüßlein³, X Mariette⁴, M Galeazzi⁵, A Cantagrel⁶, M Chartier⁷, Y Elbez⁸, C Rauch⁹ and M Le Bars⁷, ¹Schlosspark-Klinik University Medicine, Berlin, Germany, ²University Hospital, Heidelberg, Germany, ³University of Erlangen, Nürnberg, Germany, ⁴Université Paris-Sud, Paris, France, ⁵University of Siena, Siena, Italy, ⁶Purpan Hospital, Toulouse, France, ⁷Bristol-Myers Squibb, Rueil-Malmaison, France, ⁸Excelya, Boulogne-Billancourt, France, ⁹Bristol-Myers Squibb, Munich, Germany
Background/Purpose: In patients with RA, obesity may impair clinical response to anti-TNF agents.1,2 In contrast, BMI does not appear to impact treatment retention or clinical…
Abstract Number: 1601 • 2016 ACR/ARHP Annual Meeting
Maintenance Treatment Using Abatacept with Dose Reduction after Achievement of Low Disease Activity in Patients with Rheumatoid Arthritis (MATADOR) – a Prospective, Multicentered, Single Arm Clinical Trial
Shinsuke Yasuda¹, Kazumasa Ohmura¹, Hiroshi Kanazawa², Takashi Kurita¹, Yujiro Kon³, Tomonori Ishii⁴, Satoshi Jodo⁵, Kazuhide Tanimura⁶, Michio Minami⁷, Tomomasa Izumiyama⁸, Takumi Matsumoto⁹, Yoshiharu Amasaki¹⁰, Yoko Suzuki¹¹, Hideki Kasahara¹², Naofumi Yamauchi¹³, Akito Tsutsumi³, Hiromitsu Takemori², Takao Koike¹⁴ and Tatsuya Atsumi¹, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Department of Rheumatology, Aomori Prefectural Central Hospital, Aomori, Japan, ³Department of Internal Medicine, Takikawa Municipal Hospital, Takikawa, Japan, ⁴Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ⁵Department of Internal Medicine, Tomakomai City Hospital, Tomakomai, Japan, ⁶Hokkaido Medical Center for Rheumatic Diseases, Sapporo, Japan, ⁷Department of Rheumatology and Orthopaedic Surgery, Hokkaido Orthopaedic Memorial Hospital, Sapporo, Japan, ⁸Higashisendai Rheumatic Disease Clinic, Sendai, Japan, ⁹Division of Rheumatology, Kin-ikyo Chuo Hospital, Sapporo, Japan, ¹⁰The Center for Rheumatic Diseases, Tonan Hospital, Sapporo, Japan, ¹¹Izumi Himawari Clinic, Sendai, Japan, ¹²Rheumatology, NTT Sapporo Medical Center, Sapporo, Japan, ¹³Sapporo Kiyota Hospital, Sapporo, Japan, ¹⁴NTT Sapporo Medical Center, Sapporo, Japan
Background/Purpose: Aim of this study was to evaluate the feasibility of maintenance therapy with reduced dose of abatacept (ABT) to 250mg/body after achieving low disease…
Abstract Number: 1614 • 2016 ACR/ARHP Annual Meeting
Monotherapy with Abatacept, Rituximab or Tocilizumab Is Not Associated with a Significantly Lower Long Term Retention Than Combination with Synthetic DMARD: Long-Term Registry Data in 4498 Real-Life Patients with Rheumatoid Arthritis
Jacques-Eric Gottenberg¹, Jacques Morel², Arnaud Constantin³, Thomas Bardin⁴, Alain G. Cantagrel⁵, Bernard Combe⁶, Maxime Dougados⁷, Rene-Marc Flipo⁸, Alain Saraux⁹, Thierry Schaeverbeke¹⁰, Jean Sibilia¹¹, Martin Soubrier¹², Olivier Vittecoq¹³, Elodie Perrodeau¹⁴, Philippe Ravaud¹⁵, Xavier Mariette¹⁶ and on behalf of the French Society of Rheumatology and of all the investigators participating to the AIR, ORA and REGATE registries, ¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, ³Rheumatology, CHU Purpan - Hopital Pierre-Paul Riquet, Toulouse, France, ⁴Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, ⁵Rheumatology, Centre Hospitalier Universitaire, Toulouse Purpan, Toulouse, France, ⁶Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁷Rheumatology, Paris Descartes University, Paris, France, ⁸Rheumatology, University Hospital, Lille, France, ⁹Rheumatology, Brest University Hospital, Brest, France, ¹⁰Rheumatology, CHU Bordeaux, Bordeaux, France, ¹¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹²Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹³Rheumatology, Rouen University Hospital &INSERM U905, Rouen, France, ¹⁴Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ¹⁵Epidemiologist, PARIS, France, ¹⁶Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France
Background/Purpose: Data are very limited concerning the association between cotreatment with a conventional synthetic DMARD (csDMARD) and long term retention of abatacept (ABA), rituximab (RTX) and tocilizumab…
Abstract Number: 9L • 2015 ACR/ARHP Annual Meeting
A Randomized Double-Blind Trial of Abatacept and Glucocorticoids for the Treatment of Giant Cell Arteritis
Carol A. Langford¹, David Cuthbertson², Steven R. Ytterberg³, Nader A. Khalidi⁴, Paul A. Monach⁵, Simon Carette⁶, Philip Seo⁷, Larry W. Moreland⁸, Michael Weisman⁹, Curry L. Koening¹⁰, Antoine G. Sreih¹¹, Robert F. Spiera¹², Carol McAlear¹³, Kenneth J. Warrington¹⁴, Christian Pagnoux⁶, Kathleen Maksimowicz-McKinnon¹⁵, Lindsy J. Forbess¹⁶, Gary S. Hoffman¹, Renee Borchin¹⁷, Jeffrey Krischer¹⁷ and Peter A. Merkel¹⁸, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ³Rheumatology Division, Mayo Clinic, Rochester, MN, ⁴McMaster University, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁵Rheumatology, Boston University School of Medicine, Boston, MA, ⁶Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, Johns Hopkins, Baltimore, MD, ⁸Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁹Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Division of rheumatology, George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, ¹¹Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹²Rheumatology, Hospital for Special Surgery, New York, NY, ¹³Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁴Rheumatology, Mayo Clinic, Rochester, MN, ¹⁵Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁷University of South Florida, Tampa, FL, ¹⁸Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Giant cell arteritis (GCA) is a large-vessel primary systemic vasculitis. Although glucocorticoids are effective in treating GCA, they are associated with substantial toxicity and…
Abstract Number: 547 • 2015 ACR/ARHP Annual Meeting
Abatacept Does Not Improve Subclinical Atherosclerosis Despite Good Response in Rheumatoid Arthritis: A Cohort Study
Kensuke Kume¹, Kanzo Amano^1,2, Susumu Yamada¹, Toshikatsu Kanazawa³, Kazuhiko Hatta⁴, Kuniki Amano⁵ and Noriko Kuwaba⁶, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²rheumatology., hiroshima clinic, Hiroshima, Japan, ³rheumatology, hiroshima clinic, hiroshima, Japan, ⁴Rheumatology, Hatta Clinic, Kure, Japan, ⁵Rheumatology, Sky Clinic, Hiroshima, Japan, ⁶Medical Research, Sanki Clinical Link, Hiroshima, Japan
Background/Purpose: Abatacept (ABT) is very effective in treating rheumatoid arthritis(RA)1. Patients with RA have an increased risk of cardiovascular disease (CVD), and rheumatologists need to…
Abstract Number: 2766 • 2015 ACR/ARHP Annual Meeting
Glucocorticoid-Sparing Effects of Abatacept in Real Life Practice: Data from a Paneuropean Analysis of RA Registries
Jacques Gottenberg¹, Xavier Mariette², Maria Victoria Hernandez³, Florenzo Iannone⁴, Elisabeth Lie⁵, Helena Canhão⁶, Karel Pavelka⁷, Carl Turesson⁸, Merete Lund Hetland⁹ and Axel Finckh¹⁰, ¹Hautepierre, Strasbourg, France, ²Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ³Biobadaser, Barcelona, Spain, ⁴Bari University, Rheumatology, Bari, Italy, ⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Rheumatology, Lisbonne, Portugal, ⁷Charles University, Prague, Czech Republic, ⁸Lund University, Rheumatology, Dept. of Clinical Sciences,, Malmö, Sweden, ⁹DANBIO, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ¹⁰Rheumatology Division, University Hospital of Geneva, Geneva, Switzerland
Background/Purpose: Despite disease modifying anti-rheumatic drugs (bDMARDs), glucocorticoids (GCs) are still widely prescribed in rheumatoid arthritis (RA). GCs are associated with numerous potential side effects,…
Abstract Number: 560 • 2015 ACR/ARHP Annual Meeting
Impact of Anti-Citrullinated Protein Antibody Status and Response to Abatacept
Leslie Harrold^1,2, KK Gandhi³, H Litman⁴, S Kelly³, YF Li⁵, E Alemao³, S Deveikis⁴ and J Greenberg^1,6, ¹Corrona, LLC, Southborough, MA, ²Dept of Medicine, University of Massachusetts Medical School, Worcester, MA, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Corrona, LLC., Southborough, MA, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶NYU School of Medicine, New York, NY
Background/Purpose: Response to therapies may vary based on anti-citrullinated protein antibodies (ACPA) status. We compared treatment response to abatacept in ACPA-positive versus -negative RA patients…

« Previous Page
1
…
4
5
6
7
8
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].